NASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free SAGE Stock Alerts $18.74 -0.30 (-1.58%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$18.51▼$19.3450-Day Range$18.62▼$26.7152-Week Range$16.51▼$59.99Volume1.00 million shsAverage Volume963,600 shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$41.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sage Therapeutics alerts: Email Address Sage Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.18 Rating ScoreUpside/Downside118.8% Upside$41.00 Price TargetShort InterestBearish17.13% of Float Sold ShortDividend StrengthN/ASustainability-1.51Upright™ Environmental ScoreNews Sentiment0.84Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.06) to ($4.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.77 out of 5 starsMedical Sector267th out of 938 stocksPharmaceutical Preparations Industry121st out of 421 stocks 3.1 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 14 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, Sage Therapeutics has a forecasted upside of 118.8% from its current price of $18.74.Amount of Analyst CoverageSage Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.13% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 6.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 63.70% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.51. Previous Next 3.2 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Sage Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for SAGE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($6.06) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Sage Therapeutics Stock (NASDAQ:SAGE)Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More SAGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAGE Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comWe're Keeping An Eye On Sage Therapeutics' (NASDAQ:SAGE) Cash Burn RateMarch 27, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Price Target Raised to $29.00 at JPMorgan Chase & Co.March 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 27, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Shares Gap Up on Analyst UpgradeMarch 26, 2024 | markets.businessinsider.comDemystifying Sage Therapeutics: Insights From 5 Analyst ReviewsMarch 20, 2024 | msn.comThis company is treating postpartum depression in 2 weeks with a daily pillMarch 11, 2024 | barrons.comSage Therapeutics Inc.February 28, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Sage Therapeutics Through Analyst InsightsMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…February 28, 2024 | businesswire.comSage Therapeutics to Present at Upcoming March Investor ConferencesFebruary 24, 2024 | ca.finance.yahoo.comSAGE Jan 2025 30.000 putFebruary 16, 2024 | finance.yahoo.comSage Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 15, 2024 | benzinga.comThese Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 ResultsFebruary 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (SYK), SAGE Therapeutics (SAGE) and Healthcare Services (HCSG)February 15, 2024 | finance.yahoo.comSage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | msn.comPrescriptions for postpartum depression pill off to "promising" startFebruary 15, 2024 | msn.comBad News for SAGE Therapeutics, Inc. (US) Stock: This New Risk Has Been AddedFebruary 15, 2024 | finance.yahoo.comEstimating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)February 15, 2024 | markets.businessinsider.comBuy Rating for SAGE Therapeutics Amid Strong Early Demand for Zurzuvae and Solid Financial PositionFebruary 14, 2024 | marketwatch.comSage Therapeutics Shares Jump After Zurzuvae Boosts 4Q RevenueFebruary 14, 2024 | seekingalpha.comSage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 14, 2024 | markets.businessinsider.comSAGE Therapeutics, Inc. Q4 Loss decreases, beats estimatesFebruary 14, 2024 | finance.yahoo.comSage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business ProgressFebruary 14, 2024 | finance.yahoo.comSage Therapeutics Inc (SAGE) Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | businesswire.comSage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business ProgressFebruary 13, 2024 | msn.comSage Therapeutics Q4 2023 Earnings PreviewFebruary 8, 2024 | finance.yahoo.comEarnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to DeclineSee More Headlines Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/28/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees487Year FoundedN/APrice Target and Rating Average Stock Price Target$41.00 High Stock Price Target$294.00 Low Stock Price Target$20.00 Potential Upside/Downside+118.8%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($9.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-541,490,000.00 Net Margins-626.32% Pretax Margin-626.33% Return on Equity-54.41% Return on Assets-49.13% Debt Debt-to-Equity RatioN/A Current Ratio10.51 Quick Ratio10.51 Sales & Book Value Annual Sales$86.46 million Price / Sales13.03 Cash FlowN/A Price / Cash FlowN/A Book Value$13.32 per share Price / Book1.41Miscellaneous Outstanding Shares60,110,000Free Float56,801,000Market Cap$1.13 billion OptionableOptionable Beta0.87 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Barry E. Greene (Age 61)President, CEO & Director Comp: $1.29MMs. Kimi E. Iguchi CPA (Age 62)CFO & Treasurer Comp: $665.37kMs. Anne Marie Cook Esq. (Age 62)Senior VP, General Counsel & Secretary Comp: $711.6kMr. Christopher Benecchi (Age 52)Chief Business Officer Comp: $703.76kDr. Laura Gault M.D.Ph.D., Chief Medical OfficerMr. Matt LasmanisChief Technology & Innovation OfficerMr. Mike QuirkChief Scientific OfficerAshley KaplowitzDirector of Investor RelationsMs. Erin E. Lanciani (Age 55)Chief People & Experience Officer Dr. Amy Schacterle Ph.D.Senior Vice President of R&D Strategy and Business ManagementMore ExecutivesKey CompetitorsVerve TherapeuticsNASDAQ:VERVMirum PharmaceuticalsNASDAQ:MIRMCentessa PharmaceuticalsNASDAQ:CNTA89bioNASDAQ:ETNBDeciphera PharmaceuticalsNASDAQ:DCPHView All CompetitorsInsiders & InstitutionsHealthcare of Ontario Pension Plan Trust FundBought 183,607 shares on 3/21/2024Ownership: 0.335%Vanguard Group Inc.Bought 111,358 shares on 3/11/2024Ownership: 8.850%Wellington Management Group LLPSold 510,264 shares on 3/5/2024Ownership: 10.085%Fisher Asset Management LLCBought 32,306 shares on 3/5/2024Ownership: 0.719%Goldman Sachs Group Inc.Bought 163,400 shares on 3/1/2024Ownership: 0.793%View All Insider TransactionsView All Institutional Transactions SAGE Stock Analysis - Frequently Asked Questions Should I buy or sell Sage Therapeutics stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 14 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks. What is Sage Therapeutics' stock price target for 2024? 17 brokerages have issued 12 month price objectives for Sage Therapeutics' shares. Their SAGE share price targets range from $20.00 to $294.00. On average, they expect the company's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 118.8% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts. How have SAGE shares performed in 2024? Sage Therapeutics' stock was trading at $21.67 at the beginning of 2024. Since then, SAGE stock has decreased by 13.5% and is now trading at $18.74. View the best growth stocks for 2024 here. When is Sage Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our SAGE earnings forecast. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.73. The biopharmaceutical company earned $77.97 million during the quarter, compared to analysts' expectations of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative trailing twelve-month return on equity of 54.41%. The firm's revenue for the quarter was up 2621.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.47) EPS. What ETFs hold Sage Therapeutics' stock? ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Simplify Propel Opportunities ETF (SURI), ALPS Medical Breakthroughs ETF (SBIO) and Alpha Architect U.S. Quantitative Momentum ETF (QMOM).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY). Who are Sage Therapeutics' major shareholders? Sage Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (10.08%), Vanguard Group Inc. (8.86%), Vanguard Group Inc. (8.85%), RTW Investments LP (8.66%), Palo Alto Investors LP (1.65%) and Dimensional Fund Advisors LP (1.61%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SAGE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.